PR-rev2: LANDMARK STUDY: AUTISM RECOGNIZED AS MEDICALLY TREATABLE

[Guest guest]

ALL,

RE: REVISED PRESS RELEASE

Attached is a REVISED CoMeD, Inc. PRESS RELEASE

for the new study on biomarkers.

This revision is being published to remove all

references to guidelines and other publications.

Please discard the previous revision and the first

press release and use the new one that was corrected to

make it CLEARER that the press release only announces

a new study, " Autism spectrum disorder-associated

biomarkers for case evaluation and management by

clinical geneticists " published in Expert Review

of Molecular Diagnostics, and NOT some other study.

For those needing a " doc " file, please send

an email with " LSF_ARAMTR2 " in the subject line

and the reason for needing it in the body

of the e-mail and all valid requests will

be honored.

RE: THOSE NOT ACCEPTING E-MAIL ATTACHMENTS

For those who do not get SUCH, the follow-

ing is the rough-text of the Revised Press

Release's content (with the minor revisions

CAPITALIZED):

>LANDMARK STUDY: AUTISM RECOGNIZED AS MEDICALLY TREATABLE>

>REV.PRESS RELEASE CONTACTS:

>For Immediate CoMeD President [Rev. K.

>Release Sykes (Richmond, VA) ]

>December 12, 2008 CoMeD Sci. Advisor [Dr. King (Lake

> Hiawatha, NJ) ]

>

>WASHINGTON, DC - A NEW study, " Autism spectrum disorder-

>associated biomarkers for case evaluation and management

>by clinical geneticists " in Expert Review of Molecular

>Diagnostics,[1] confirms that there are now well-estab-

>lished, routine, clinically available, identified

>biomarkers to help clinical geneticists medically

>evaluate and treat individuals diagnosed with an ASD

>and briefly outlines some recognized biomarkers.

>Depending on the cause of the ASD, these researchers

>have found that " associated medical risks may be

>identified, which may lead to screening and poten-

>tial morbidity prevention in patients and other

>family members. " The non-profit CoMeD, Inc., and,

>through a grant from the Brenen Hornstein Autism

>Research & Education (BHARE) Foundation, the non-

>profit Institute of Chronic Illnesses, Inc. funded

>this NEW study.

>

>The important clinical tools identified for medical

>evaluation and treatment response monitoring included:

>

>q Pophyrin biomarkers - to help determine if mercury

> toxicity is present, and, when it is found, to

> monitor changes in mercury-burden during detoxifi-

> cation therapies.

>

>q Trans-Sulfuration biomarkers - to help determine

> if mercury biochemical susceptibility is present

> and, when it is found, to monitor patient response

> during supplementation with nutritional therapies

> such as methylcobalamin (the methyl form of vita-

> min B12), folinic acid, and pyroxidine (vitamin B6).

>

>q Oxidative Stress/Inflammation biomarkers - to help

> determine if there are excessive by-products of

> metabolic pathways, and, when they are found, to

> monitor patient progress during supplementation

> with anti-inflammatory drugs such as Aldactone®

> (spironolactone).

>

>q Hormonal biomarkers - to help determine if hormonal

> abnormalities are present and, when they are found,

> to monitor patient progress during the indicated

> treatment with hormonal regulation drugs such as

> Lupron® (leuprolide acetate) and Yaz® (drospirenone/

> ethynyl estradiol).

>q Mitochondrial Dysfunction biomarkers - to help de-

> termine if there are disruptions in the energy pro-

> duction pathways, and, when they are found, to

> monitor patient progress during supplementation

> with drugs such as Carnitor® (L-carnitine).

>

>q Genetic biomarkers - to help determine if there

> are genetic causal or susceptibility factors

> present, and, when they are found, to provide

> insights into behavior modification to help re-

> duce the impact of such genetic factors.

>

>Today, any parent, physician, or healthcare provi-

>der can easily engage the services of a qualified

>clinical geneticist to help evaluate and treat

>those diagnosed with an ASD by contacting ASD Clinics,

>LLC, a national outreach clinic helping to provide

>clinical genetic services through the Genetic

>Centers of America. For information about sched-

>uling a consultation, please call .

>

>Current Consultation Center Locations:

>West Coast - Genetic Consultants of Washington

> State (Seattle, WA)

>Central - Genetic Consultants of Indianapolis

> (Indianapolis, IN)

>East Coast - Genetic Consultants of land

> (Washington, DC)

>

>Your generous tax-free donations will help us to

>fund additional research, similar to the present

>study, to examine the biomedical basis and

>treatments for patients diagnosed with an ASD.

>

>=================================================

>

>To support the ongoing efforts of CoMeD, Inc.

>with your tax-deductible contributions, please use

>the PayPal link on CoMeD's Internet website,

> http://www.Mercury-freeDrugs.org.

>CoMeD, Inc. is a not-for-profit 501©(3) corpora-

>tion that is actively engaged in legal, educational

>and scientific efforts to stop all use of mercury

>in medicine, and to ban the use of all mercury-

>containing medicines.

>

>ENDNOTE

>[1] Geier Da, Geier MR. Expert. Rev. Mol. Diagn. 2008;

> 8(6): 671-674.

>

Hopefully, most will find this

Press Release to be informative.

*******************************************

*The information provided in this email *

*and any attachment thereto is just that *

* -- information. *

* *

*It is not medical advice and it does not *

*require any specific action or actions. *

* *

*While the information is thought to be *

*accurate, no representation is made as *

*to the accuracy of the information posted*

*other than it is my best understanding of*

*the facts on the date that this email and*

*any attachments thereto are posted. *

* *

*Everyone should verify the accuracy of *

*the information provided for themselves *

*before acting on it. *

*******************************************

Respectfully,

Dr. King

http://www.dr-king.com

+++++++++++++++++++++++++++++++++++++++++++